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OBJECTIVES The object of the study was to assess the relationship between erythrocyte sedimentation rate
(ESR) and inflammatory cytokine production in chronic heart failure (CHF). Our findings
lead us to re-evaluate the prognostic value of the ESR in assessing patients with CHF.
BACKGROUND The search for simple prognostic markers in CHF that can be assessed anywhere at low cost
is important. Increases in ESR are related to the acute phase response in states of
inflammation and infection.
METHODS Initially, we studied ESR in relation to plasma levels of inflammatory cytokines in 58 CHF
patients. The findings prompted us to analyze the mortality predictive power of ESR
compared with established risk factors in these patients and (retrospectively) in a second
group of 101 clinically stable CHF patients who had ESR measured.
RESULTS In all 159 CHF patients (age 62 6 2 years, New York Heart Association [NYHA] class 2.7 6
0.1), ESR ranged from 1 to 96 mm/h (median 14 mm/h). The ESR was correlated with
tumor necrosis factor (TNF)-alpha (r 5 0.31, p , 0.05), soluble TNF receptor-1 (r 5 0.48,
p , 0.0005), soluble TNF receptor-2 (r 5 0.39, p , 0.005) and interleukin 6 (r 5 0.45, p ,
0.005) levels. High ESR levels indicated a poor prognosis (p , 0.0001), and this was
independent of age, NYHA class, ejection fraction and peak oxygen consumption (p ,
0.005). Patients with ESR above median ($15 mm/h) compared with patients with ESR
,15 mm/h had an impaired survival (hazard ratio 2.62, 95% confidence interval 1.58–4.36,
p , 0.0001).
CONCLUSIONS Our study demonstrates that in CHF a high ESR is an unfavorable prognostic sign,
independent of patients’ symptomatology and ventricular function. These results are in
diametrical contrast to previous results. This may reflect a change in the underlying
pathophysiology due to today’s treatment with angiotensin-converting enzyme inhibitors. (J
Am Coll Cardiol 2000;36:523–8) © 2000 by the American College of Cardiology
The search for markers of prognosis in chronic heart failure
(CHF) is important. Of particular interest are markers that
can be assessed anywhere at (nearly) no cost. The use of
angiotensin-converting enzyme (ACE) inhibitors for the
treatment of CHF patients started only about 10 years ago.
This major treatment change might have affected the
strength or even the direction of prognostic markers estab-
lished in the pre-ACE inhibitor era. The possibility that the
introduction of new therapies can reverse the direction of
conventional prognostic markers is a novel concept that may
be applicable to many other diseases. To our knowledge this
phenomenon has never been shown before, and this may
have implications for other prognostic markers that are
currently used in the management of cancer, infectious
diseases or other chronic illnesses.
The erythrocyte sedimentation rate (ESR) is a particu-
larly simple measure of clinical status. It has been available
to physicians for over eight decades (1), but its value in
clinical cardiology is controversial (2). In 1991, Haber et al.
(3) reported that a low ESR was associated with an
unfavorable prognosis in 242 patients with heart failure.
When these patients were re-evaluated after the introduc-
tion of new treatments, the clinical improvement and the
changes in hemodynamic status were directly related to an
increase in ESR. These findings appear to contradict our
clinical experience suggesting that a high ESR is a reflection
of an acute phase response to inflammation, or infection is
present (4), and that it is usually associated with a poor
clinical outcome. Since 1991, no single study has been
published on ESR in CHF patients.
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Initially, we intended to assess the relationship between
ESR and inflammatory cytokines and markers of cytokine
production in CHF. Our findings lead us to re-evaluate the
prognostic value of ESR in assessing patients with CHF.
Our results show the opposite of previous findings (3). We
put forward a hypothesis to explain the apparent change in
the relationship between the ESR and survival in CHF.
METHODS
Study population and follow-up. We performed a pro-
spective study assessing inflammatory cytokines and ESR in
58 stable patients with CHF (age 61 6 1, New York Heart
Association [NYHA] class 2.7 6 0.1, left ventricular
ejection fraction [LVEF] 27 6 2%, mean duration of heart
failure 5 6 1 years). The study was approved by the local
ethics committee, and all patients and controls gave written
informed consent. The results from this study prompted us
to analyze mortality in these 58 patients and (retrospective-
ly) in a second group of 101 clinically stable CHF patients
(age 63 6 1, NYHA class 2.7 6 0.1, LVEF 30 6 2%) who
had ESR measured between May 1992 and June 1998 as
part of their routine clinical investigations. The clinical
characteristics (age, NYHA class, LVEF and peak oxygen
consumption) did not differ significantly between the two
study groups (all p . 0.3). Results of survival analyses (using
the Cox proportional hazards model) also did not demon-
strate a significant difference between the two groups.
Baseline clinical details are, therefore, reported for the
whole study population in Table 1.
The diagnosis of CHF was based on clinical presentation
and standard investigations. The 159 CHF patients were
aged 28 to 87 years (mean 62 6 2 years). The majority of
patients (92%) were in NYHA class II to IV (64% were in
class III and IV), and 85% were on an ACE inhibitor (see
Table 1). The etiology of CHF was ischemic in 72% of
patients and idiopathic dilated cardiomyopathy in 28%. In
130 patients LVEF was determined by radionuclide ven-
triculography or echocardiography. A total of 125 patients
underwent treadmill exercise testing with respiratory gas
analysis, and the mean peak oxygen consumption (VO2) was
16.8 6 0.6 ml/kg/min. Patients were excluded from the
study if they were clinically unstable, were edematous or had
severe renal failure. No subject had clinical signs of infec-
tion, rheumatoid arthritis or cancer at the time of ESR
assessment. Follow-up for survival status (as of 31/12/98)
was available in March/April 1999 from the hospital infor-
mation system and from the Office of National Statistics
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ACE 5 angiotensin-converting enzyme
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Table 1. Clinical Characteristics of 159 CHF Patients
All CHF
(n 5 159)
Patients With
ESR <15 mm/h
(n 5 80)
Patients With
ESR >15 mm/h
(n 5 79)
Age (yrs) 62 6 2 60 6 1 64 6 1*
NYHA class
mean 2.7 6 0.1 2.6 6 0.1 2.8 6 0.1
I (n) 12 (12) 8 4
II (n) 46 (46) 24 22
III (n) 80 (80) 40 40
IV (n) 21 (21) 8 13
LVEF (%) 29 6 1 29 6 2 28 6 2
(n) (130) (65) (65)
ESR (mm/h) 19.6 6 1.4 6.9 6 0.4 32.5 6 2.0§
Patients on ACE
inhibitor therapy
135 (85%) 65 (81%) 70 (89%)
TNF alpha (pg/ml) 9.34 6 1.12 6.85 6 0.68 12.21 6 2.18*
(n) (58) (31) (27)
sTNFR-1 (pg/ml) 1,333 6 135 902 6 73 1,831 6 247‡
(n) (58) (30) (26)
sTNFR-2 (pg/ml) 2,434 6 133 2,082 6 146 2,840 6 207†
(n) (58) (30) (26)
IL-6 (pg/ml) 3.35 6 0.41 2.00 6 0.22 4.80 6 0.72‡
(n) (58) (30) (28)
Patients have also been subdivided on the basis of median ESR (values are mean 6 SEM). *p , 0.05; †p , 0.005; ‡p , 0.001;
§p , 0.0001.
ACE 5 angiotensin-converting enzyme; CHF 5 chronic heart failure; ESR 5 erythrocyte sedimentation rate; IL-6 5
interleukin 6; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association; sTNFR 5 soluble tumor
necrosis factor receptor; TNF 5 tumor necrosis factor.
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where all patients had been flagged for death as part of the
Royal Brompton Hospital heart failure registry.
ESR and cytokine analyses. Erythrocyte sedimentation
rate was analyzed using standard procedures. The cytokine
assays were performed on EDTA plasma from venous blood
samples taken from patients after an overnight fast and after
at least 20 min of supine rest. Tumor necrosis factor alpha
(TNF alpha) levels were measured using an ELISA assay
(Medgenix, Fleurus, Belgium, sensitivity 3 pg/ml). As TNF
alpha levels are known to be variable due to a short plasma
half-life time, we also measured the more stable soluble
TNF receptors (sTNFR)-1 and -2 using ELISA tests
(R&D Systems, Minneapolis, Minnesota; sensitivity 25 and
2 pg/ml, respectively). Interleukin 6 (IL-6) levels were also
measured using an ELISA assay (R&D Systems, Minne-
apolis, Minnesota; sensitivity 0.094 pg/ml).
Statistics. All results are presented as mean value 6 SEM.
Unpaired Student t tests and both univariate and multivar-
iate regression analysis were performed. Cox proportional
hazard analysis was used to assess the association between
variables and all-cause mortality. Hazard ratio (RR) and
95% confidence interval (CI) for risk factors as well as
significance levels for chi-square (likelihood ratio test) are
given, and Kaplan-Meier cumulative survival plots were
constructed (StatView 5, Abacus Concepts, Berkeley,
California).
RESULTS
In the 58 patients initially studied, a mean ESR of 19 6
2 mm/h (range 1 to 96 mm/h) was found. Plasma levels of
TNF alpha (p , 0.05), sTNFR-1 and sTNFR-2 (both
p , 0.001, Table 1) were higher than in healthy control
subjects of similar age reported earlier (5). Regression
analyses showed that the ESR was positively correlated with
TNF alpha (r 5 0.31, p , 0.05), sTNFR-1 (r 5 0.48, p ,
0.0005, Fig. 1), sTNFR-2 (r 5 0.39, p , 0.005) and IL-6
(r 5 0.45, p , 0.005) levels. The second group of 101 CHF
patients showed a mean ESR of 20 6 2 (p . 0.5 vs. first
study group).
Considering all 159 CHF patients, the ESR ranged from 1
to 96 mm per h (median 14). When patients were grouped for
ESR above median (i.e., $15 mm/h, n 5 79, mean: 32 mm/h)
and ESR ,15 mm/h (n 5 80, mean: 7 mm/h), patients with
low ESR were, on average, four years younger (p , 0.05), but
NYHA class, LVEF and the proportion of patients treated
with ACE inhibitors were similar (Table 1). There were 26
patients (16%) who had an ESR , 5 mm/h. The mean
furosemide equivalent dose for the patients in the study was
101 6 10 mg. There was a weak correlation between ESR and
age (r 5 0.16, p 5 0.046), but ESR did not correlate with
NYHA class, LVEF, duration of CHF and diuretic dose (all
p . 0.11). During follow-up (duration 7 to 80 months in
survivors, mean 37 6 3 months), 66 (42%) of the 159 CHF
patients died after 2 to 2,443 days (median 569 days). All
deaths could be attributed to cardiovascular causes or were of a
sudden nature.
In both studies ESR was associated with an impaired
survival in CHF patients (prospectively studied patients RR
1.031, p 5 0.0016; retrospective study RR 1.026, p 5 0.0009).
In both studies this was independent of age and NYHA class
(data not shown). In the combined data set, survival analyses
showed that a high ESR is associated with an impaired survival
(p , 0.0001, Table 2). Every mm increase of ESR was related
to a 2.9% higher risk (95% CI 1.8–3.9%) of death during
follow-up. The group of patients with high ESR ($15 mm/h)
had an impaired survival compared with patients with ESR
,15 mm/h (RR 2.62, 95% CI 1.58–4.36, p , 0.0001, Fig. 2).
The negative prognostic value of high ESR was independent of
age, NYHA class, LVEF (p , 0.0001) and peak VO2 (p ,
0.005, Table 2). When restricting the survival analysis to
patients with an LVEF ,30% (n 5 75, mean 17 6 1%), a
high ESR remains predictive of an impaired prognosis (RR
1.029, p , 0.0001).
Considering an ESR cut-off value of 25 mm/h (previous-
ly used in reference 3), patients with ESR .25 mm/h had
a worse prognosis than patients with ESR #25 mm/h (RR
3.70, 95% CI 2.27–6.00, p , 0.0001). The mortality
predictive power of high ESR was similar in the subgroup of
135 patients treated with an ACE inhibitor (ESR in mm/h:
p , 0.0001, ESR # 25 mm/h: p , 0.0001) and in the
group of 101 patients with NYHA class III and IV (ESR in
mm/h: p 5 0.0002, ESR # 25 mm/h: p , 0.0001). Also,
in the subgroup of 58 patients in NYHA I/II, a high ESR
related to a poor prognosis (p , 0.0005).
We categorized patients according to whether they were
taking a high, medium or low dose of an ACE inhibitor (at the
time of assessment), but we found no significant correlation
between ACE inhibitor dose and ESR (data not shown).
DISCUSSION
This study shows that in CHF patients, the ESR is
positively correlated with plasma levels of inflammatory
cytokines. An increased ESR is a strong predictor of
impaired survival in patients with CHF, independent of
Figure 1. The correlation between ESR and soluble TNF receptor-1
plasma levels in 58 patients with CHF. CHF 5 chronic heart failure;
ESR 5 erythrocyte sedimentation rate; sTNFR 5 soluble tumor necrosis
factor receptor.
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established risk factors such as NYHA class, LVEF and
peak VO2. This study shows for the first time that, in
patients with a well-known and frequent chronic disease, it
is possible that a parameter that was previously thought to
relate to a better prognosis can (within 10 years) become a
predictor of impaired survival.
In this study, only 16% of patients had an ESR ,
5 mm/h, which is similar to what was reported by Haber
and colleagues (3) (10% of patients in their study had an
ESR , 5 mm/h). Therefore, this tends to support the
hypothesis that the ESR is high in CHF. However, the
important difference between Haber’s study and the present
one is in the prognostic value of the ESR in CHF. Our
results are in contrast to the study of Haber et al. (3) where
high ESR levels (.25 mm/h, median in their study)
indicated better survival in 242 patients with CHF. These
patients were nonedematous, in NYHA class III and IV,
and, at baseline, these patients had been treated with
diuretics and digitalis. Only during follow-up (i.e., after the
initial ESR assessment) were patients treated with ACE
inhibitors (n 5 126), other vasodilators (n 5 106) or
amrinone (n 5 3). Haber et al. (3) also demonstrated for 35
patients (15% of their total study group) that after one to
three months of this new therapy, patients whose ESR
increased showed improvement in both cardiac performance
and functional status. These results were in agreement with
Paul Wood’s (6) findings in 1936, when he reported on 22
patients with heart failure and found that the ESR de-
creased as heart failure worsened and rose again when the
condition improved.
The results of our investigations apparently contradict
those of the previous studies. We have no reason to doubt
that both the older studies and ours correctly describe the
role of the ESR in heart failure. If that is so, there must be
a fundamental difference between the studies to explain the
Figure 2. Kaplan-Meier survival plot for 159 patients with chronic heart
failure. Patients were subgrouped according to erythrocyte sedimentation
rate (ESR).
Table 2. Cox Proportional Hazards Analysis of Survival in 159 CHF Patients
Parameter
Chi-Square
Value p Value RR (95% CI)
Univariate analysis
Age (yrs) 15.4 , 0.0001 1.047 (1.023–1.071)
ESR (mm/h) 22.6 , 0.0001 1.029 (1.018–1.039)
ESR (,15, $15 mm/h) 14.7 , 0.0001 2.623 (1.577–4.363)
ESR (#25, .25 mm/h) 25.0 , 0.0001 3.697 (2.270–6.002)
NYHA class 8.8 0.003 1.607 (1.165–2.218)
LVEF (%), n 5 130 3.7 0.055 0.981 (0.962–1.001)
Peak VO2 (ml/kg/min), n 5 125 25.7 , 0.0001 0.865 (0.812–0.921)
Multivariate analysis
Age (yrs) 10.6 0.002 1.025 (1.014–1.036)
NYHA class 5.5 0.02 1.540 (1.075–2.207)
ESR (mm/h) 20.0 , 0.0001 1.025 (1.013–1.063)
ESR (mm/h) 26.7 , 0.0001 1.029 (1.018–1.041)
LVEF (%), n 5 130 3.2 0.07 0.982 (0.962–1.002)
ESR (mm/h) 8.1 0.004 1.030 (1.011–1.048)
Peak VO2 (ml/kg/min), n 5 125 10.2 0.001 0.877 (0.806–0.955)
Age (yrs) 2.9 0.09 1.030 (0.995–1.065)
LVEF (%) 2.6 0.11 0.982 (0.959–1.004)
ESR (#25, .25 mm/h) 8.2 0.004 2.523 (1.340–4.751)
Peak VO2 (ml/kg/min), n 5 116 6.9 0.008 0.913 (0.853–0.977)
CHF 5 chronic heart failure; CI 5 confidence interval; ESR 5 erythrocyte sedimentation rate; IL-6 5 interleukin 6; LVEF 5
left ventricular ejection fraction; NYHA 5 New York Heart Association; RR 5 hazards ratio; VO2 5 oxygen consumption.
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diametrically opposed results. The technique for measuring
the ESR has not changed in the past few decades. In
Haber’s study (3) as well as in ours, nonedematous CHF
patients were studied. The major difference between the
study populations is treatment with ACE inhibitors. In our
study the majority of patients were taking ACE inhibitors
(85%), whereas at initial investigation none of the patients
studied by Haber et al. (3) and Wood (6) were on this
therapy.
The role of ACE inhibitors. What may be the importance
of ACE inhibitors causing a fundamental change in the
relationship between the ESR and survival in CHF?
Changes in ESR are part of body’s acute phase response to
illness (4). It could be hypothesized that, before the advent
of ACE inhibitors, patients with CHF were compromised
in their response to the disease. Independently of symptom-
atology (i.e., NYHA class) and ventricular function (i.e.,
LVEF) patients with a high ESR (and without an ACE
inhibitor) may have represented those patients who were
able to respond adequately to metabolic and immunological
abnormalities, and, thus, these patients had a more favorable
outcome. Patients with low ESR were compromised in their
responsiveness and died earlier. When new treatment was
started, measures of heart failure status improved, the
response to metabolic and immunological abnormalities
improved, and ESR was then found to increase proportion-
ally. Today most patients are on long-term ACE inhibitor
therapy, which may result in an intact responsiveness and a
different meaning of a high or low ESR. When the
metabolic/immunological CHF status is normal (again,
independently of NYHA class and LVEF), no stress is
present, ESR is low, and the prognosis is favorable. When
the CHF status is poor, metabolic/immunological abnor-
malities are present, ESR is high, and the prognosis is
impaired.
Inflammatory cytokines and the ESR. In support of the
above hypothesis, we found that ESR is significantly and
positively correlated with markers of inflammatory immune
activation. These correlations, and the prognostic results for
ESR, support the hypothesis that inflammatory cytokines
(particularly TNF receptors) in their own right are strongly
related to impaired prognosis in CHF. There is some
preliminary evidence for the latter (7).
The ESR is not only a marker of inflammation but also of
infectious processes. We have hypothesized that bacterial
lipopolysaccharide may play a role in the immune activation
of CHF patients (8), and it has been shown that increased
lipopolysaccharide-inducible TNF alpha production of pe-
ripheral monocytes (9) and cardiomyocytes (10) can be
observed in a proportion of CHF patients. Angiotensin-
converting enzyme inhibitors have been found to be able to
suppress lipopolysaccharide-induced production of TNF
alpha in vitro and in vivo (11). Metabolic and immunolog-
ical abnormalities are strongest in patients with cardiac
cachexia (12). If an ACE inhibitor makes a patient more
tolerant to pathophysiological changes, this may also pre-
vent the development of cachexia in CHF. There is evi-
dence for the latter (13).
Our model of impaired metabolic and immunological
responsiveness in CHF patients somewhat resembles the
picture of immune incompetence seen in a number of
patients with bacterial sepsis. In sepsis, depending on the
precise time point of investigation or initiation of treatment,
high, and, in other cases, low levels of inflammatory
cytokines may predict poor outcome (14), and immune
system stimulatory treatment (with interferon-gamma in
patients with an exhausted or incompetent immune system
[15]) or immune system inhibitory treatment (for instance
with TNF antibodies in patients with high cytokine levels
[16]) may improve outcome. Nevertheless, it is difficult to
test our hypothesis prospectively. Today, if CHF patients
are not treated with ACE inhibitors, they may receive
angiotensin 2 receptor blockers. An increasing number of
CHF patients also receive beta-adrenergic blocking agent
treatment that has been proven to exert survival benefit (17),
and these new treatments may have similar metabolic effects
to those of ACE inhibitors. Withholding these treatments
is not possible.
Angiotensin-converting enzyme inhibitor dose was not
related to ESR. We appreciate that there is no ideal method
to compare ACE inhibitor doses as various ACE inhibitors
have differing pharmacological properties. We were not able
to analyze the mean drug dose over time. A comparison
between patients taking and not taking ACE inhibitors is
not feasible due to the low number of patients in this study
not on ACE inhibitors (15%). Fourteen of the 24 patients
not on an ACE inhibitor at the time of investigation had
previously been on an ACE inhibitor for at least three
months.
The precise mechanism whereby ACE inhibitors appear
to change the relationship between ESR and patients’
survival are not known. Our hypothesis may be one expla-
nation. Alternatively, CHF patients may now live longer
(on ACE inhibitors). The somewhat worse general survival
and higher median ESR in the previous study (3) may
indicate a moribund population with more severely impaired
liver function. The introduction of ACE inhibitor therapy
in the previous study may have transiently allowed improved
liver function with an initial increase in inflammatory
mediators, hence, the increased ESR as patients began to
improve clinically.
In many chronic diseases, new drugs are developed as a
result of advances in basic and clinical research. Some of
them may dramatically alter the pathophysiology of the
disease and may lead to changes in the prognostic value of
“well established” survival indicators. Doctors, scientists and
other health care professionals need to be aware of this
phenomenon when assessing the value of conventional
prognostic indicators. We believe that this phenomenon
could also be relevant to cancer, infectious diseases and
other chronic conditions where novel treatments are devel-
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oped. To our knowledge this has never been shown before,
and, therefore, this finding may be of major significance.
Conclusions. This study shows that in heart failure, as is
the case in many other diseases, a high ESR is a bad
prognostic sign. The prognostic value of the ESR in CHF
patients is independent of patients’ symptomatology and
ventricular function. These results are in contrast to previ-
ous work. We hypothesize that today’s treatment with ACE
inhibitors may improve patients’ responsiveness to meta-
bolic and immunological abnormalities. In a chronic disease
an “established” prognosticator can potentially, on the
background of new treatment, completely change its clinical
information value to predict the opposite outcome. This
could be relevant for other “long-established” survival mark-
ers in heart failure as well as other diseases.
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